Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare limited - phenoxymethylpenicillin - film coated tablet - 250 milligram - phenoxymethylpenicillin

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin potassium, quantity: 560 mg (equivalent: phenoxymethylpenicillin, qty 500 mg) - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; vanillin; quinoline yellow; purified talc; xanthan gum; polyvinyl alcohol; lecithin; hypromellose; macrogol 6000 - treatment of mild to moderately severe infections caused by penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham?s chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note: oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or childbirth.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin potassium, quantity: 280 mg (equivalent: phenoxymethylpenicillin, qty 250 mg) - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; vanillin; quinoline yellow; purified talc; xanthan gum; polyvinyl alcohol; lecithin; hypromellose; macrogol 6000 - treatment of mild to moderately severe infections caused by penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham?s chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note: oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or childbirth..

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - phenoxymethylpenicillin potassium 28.284 mg/ml equivalent to 25 mg/ml phenoxymethylpenicillin.;  ;   - granules for oral solution - 125 mg/5ml - active: phenoxymethylpenicillin potassium 28.284 mg/ml equivalent to 25 mg/ml phenoxymethylpenicillin.     excipient: orange 175-78-8 orange flavour j1978 10814413 saccharin sodium sodium benzoate sucrose as caster sugar. - treatment of mild to moderately severe infections caused by penicillin-sensitive organisms. the following infections will usually respond to an adequate dosage of penicillin.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - phenoxymethylpenicillin potassium 56.568 mg/ml equivalent to 50 mg/ml phenoxymethylpenicillin;  ;   - granules for oral solution - 250 mg/5ml - active: phenoxymethylpenicillin potassium 56.568 mg/ml equivalent to 50 mg/ml phenoxymethylpenicillin     excipient: orange 175-78-8 orange flavour j1978 10814413 saccharin sodium sodium benzoate sucrose as caster sugar. - treatment of mild to moderately severe infections caused by penicillin-sensitive organisms. the following infections will usually respond to an adequate dosage of penicillin.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - phenoxymethylpenicillin potassium 279mg equivalent to phenoxymethylpenicillin 250 mg (actual formula based on 100% potency); phenoxymethylpenicillin potassium 277.18mg equivalent to phenoxymethylpenicillin 250 mg; phenoxymethylpenicillin potassium 277.18mg equivalent to phenoxymethylpenicillin 250 mg; phenoxymethylpenicillin potassium 277.18mg equivalent to phenoxymethylpenicillin 250 mg - capsule - 250 mg - active: phenoxymethylpenicillin potassium 279mg equivalent to phenoxymethylpenicillin 250 mg (actual formula based on 100% potency) excipient: brilliant blue fcf erythrosine gelatin magnesium stearate opacode white s-1-7085 sunset yellow fcf titanium dioxide active: phenoxymethylpenicillin potassium 277.18mg equivalent to phenoxymethylpenicillin 250 mg excipient: capsugel orange op.c027 magnesium stearate active: phenoxymethylpenicillin potassium 277.18mg equivalent to phenoxymethylpenicillin 250 mg excipient: capsugel orange op.c027 magnesium stearate active: phenoxymethylpenicillin potassium 277.18mg equivalent to phenoxymethylpenicillin 250 mg excipient: gelatin capsule - maroon - mi01429 gelatin capsule - maroon - mi01430 magnesium stearate - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - phenoxymethylpenicillin potassium 544.37mg equivalent to phenoxymethylpenicillin 500 mg; phenoxymethylpenicillin potassium 544.36mg equivalent to phenoxymethylpenicillin 500 mg; phenoxymethylpenicillin potassium 554.37mg equivalent to phenoxymethylpenicillin 500 mg - capsule - 500 mg - active: phenoxymethylpenicillin potassium 544.37mg equivalent to phenoxymethylpenicillin 500 mg excipient: gelatin magnesium stearate active: phenoxymethylpenicillin potassium 544.36mg equivalent to phenoxymethylpenicillin 500 mg excipient: capsugel orange op.c027 gelatin iron oxide red magnesium stearate titanium dioxide active: phenoxymethylpenicillin potassium 554.37mg equivalent to phenoxymethylpenicillin 500 mg excipient: maroon capsule acg associated capsules pvt. ltd magnesium stearate - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation.

Namibia - English - Namibia Medicines Regulatory Council

milan laboratories (india) pvt ltd - phenoxymethylpenicillin potassium - powder for reconstitution - each 5ml of reconstituted solution contains phenoxymethylpenicillin potassium bp equivalent to phenoxymethylpenicillin 250,0 mg

Namibia - English - Namibia Medicines Regulatory Council

milan laboratories (india) pvt ltd - phenoxymethylpenicillin potassium - powder for reconstitution - each 5ml of reconstituted solution contains phenoxymethylpenicillin potassium bp equivalent to phenoxymethylpenicillin 125,0 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - phenoxymethylpenicillin potassium - oral solution - 25mg/1ml